Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer

Lung Cancer

Volumn 69, Issue 3, 2010, Pages 259-264

  Laack, Eckart ^a   Sauter, Guido ^b   Bokemeyer, Carsten ^b  

^a Ambulantes Krebszentrum Hamburg   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

EGFR; Erlotinib; Gefitinib; Inhibitors; Kinase; NSCLC

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AV 412; AZD 8931; CANERTINIB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; INSULIN RECEPTOR SUBSTRATE 1; LAPATINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PACLITAXEL; PELITINIB; PF 299804; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER RESEARCH; CLINICAL TRIAL; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 77955095069     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.05.015     Document Type: Review

References (79)

1. WHO. Revised Global Burden of Disease (GBD) 2002 estimates: incidence, prevalence, mortality, YLL, YLD and DALYs by sex, cause and region, estimates for 2002 as reported in the World Health Report 2004. Geneva: World Health Organisation; 2004.
2. Navada S., Lai P., Schwartz A.G., Kalemkerian G.P. Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database. J Clin Oncol 2006, 24:384S.
3. Sher T., Dy G.K., Adjei A.A. Small cell lung cancer. Mayo Clin Proc 2008, 83:355-367.
4. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594.
5. BTS. Guidelines on the selection of patients with lung cancer for surgery. British Thoracic Society and Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. Thorax 2001;56:89-108.
6. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
7. Lin W.C., Chiu C.H., Liou J.L., Chen Y.M., Perng R.P., Tsai C.M. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 2006, 54:193-199.
8. Yang CH, Yu CJ, Shih JY, Tsai MC, Chen KY, Lin ZZ et al. A prospective study assessing tumor response of gefitinib in chemonaive good performance advanced stage nonsmall cell lung cancer (NSCLC) patients with different types of Epidermal Growth Factor Receptor (EGFR) mutations:P3-158. J Thorac Oncol 2007 Aug;2(8 Suppl. 4):S137-852.
9. Kimura H., Kasahara K., Shibata K., Sone T., Yoshimoto A., Kita T., et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006, 1:260-267.
10. Niho S., Kubota K., Goto K., Yoh K., Ohmatsu H., Kakinuma R., et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006, 24:64-69.
11. Suzuki R., Hasegawa Y., Baba K., Saka H., Saito H., Taniguchi H., et al. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer 2006, 94:1599-1603.
12. Lee D.H., Han J.Y., Lee H.G., Lee J.J., Lee E.K., Kim H.Y., et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005, 11:3032-3037.
13. Mok T., Wu Y., Thongprasert S., Yang C., Chu D., Saijo N., et al. Phase III, randomized, open-label, first-line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced NSCLC (IPASS). Ann Oncolog 2008, 19. [abstract LBA2].
14. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
15. Gettinger S. Targeted therapy in advanced non-small-cell lung cancer. Semin Respir Crit Care Med 2008, 29:291-301.
16. Li D., Shimamura T., Ji H., Chen L., Haringsma H.J., McNamara K., et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007, 12:81-93.
17. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
18. Normanno N., Bianco C., Strizzi L., Mancino M., Maiello M.R., De Luca A., et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005, 6:243-257.
19. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-3167.
20. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272.
21. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516.
22. Wieduwilt M.J., Moasser M.M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008, 65:1566-1584.
23. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998, 77:663-669.
24. Ohsaki Y., Tanno S., Fujita Y., Toyoshima E., Fujiuchi S., Nishigaki Y., et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000, 7:603-607.
25. Garcia de Palazzo I.E., Adams G.P., Sundareshan P., Wong A.J., Testa J.R., Bigner D.D., et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993, 53:3217-3220.
26. Pedersen M.W., Meltorn M., Damstrup L., Poulsen H.S. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001, 12:745-760.
27. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009, 21:177-184.
28. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 7(Suppl. 4):2-8.
29. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
30. Blackhall F., Ranson M., Thatcher N. Where next for gefitinib in patients with lung cancer?. Lancet Oncol 2006, 7:499-507.
31. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
32. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
33. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. Journal of Clinical Oncology 2009, 27(Suppl. 15). [abstract 8001].
34. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
35. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
36. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25:1545-1552.
37. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:5892-5899.
38. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
39. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
40. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
41. Sequist L.V., Lynch T.J. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008, 59:429-442.
42. Rosell R., Provencio M., Domine M., Pradas A., Salazar F., Reguart N., et al. Spanish Lung Adenocarcinoma Trial (SLAT) of customized treatment based on EGFR mutations (mut) and BRCA1 mRNA expression: Ancillary analyses of Abraxas and RAP80 expression. J Clin Oncol 2008, 26. [abstract 8037].
43. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
44. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744-52.
45. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
46. Giaccone G., Rodriguez J.A. EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nat Clin Pract Oncol 2005, 2:554-561.
47. Kim T.Y., Han S.W., Bang Y.J. Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Rev Mol Diagn 2007, 7:821-836.
48. Sequist L.V., Bell D.W., Lynch T.J., Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007, 25:587-595.
49. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
50. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
51. Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
52. Guix M., Faber A.C., Wang S.E., Olivares M.G., Song Y., Qu S., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118:2609-2619.
53. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
54. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
55. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13:2890-2896.
56. Yun C.H., Mengwasser K.E., Toms A.V., Woo M.S., Greulich H., Wong K.K., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
57. Wong K.K. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Lung Cancer 2008, 60(Suppl. 2):S10-S18.
58. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005, 2:e313.
59. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102:7665-7670.
60. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
61. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.K., Tenen D.G., et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005, 65:7096-7101.
62. Shimamura T., Ji H., Minami Y., Thomas R.K., Lowell A.M., Shah K., et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006, 66:6487-6491.
63. Yuza Y., Glatt K.A., Jiang J., Greulich H., Minami Y., Woo M.S., et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 2007, 6:661-667.
64. Shimamura T., Gewulich H., Solca F., Wong K. Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model. J Thorac Oncol 2007, 2:S380.
65. Suzuki T., Fujii A., Ohya J., Nakamura H., Fujita F., Koike M., et al. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Cancer Sci 2009, 100:1526-1531.
66. Nelson M.H., Dolder C.R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006, 40:261-269.
67. Janmaat M.L., Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2003, 8:576-586.
68. Yoshimura N., Kudoh S., Kimura T., Mitsuoka S., Matsuura K., Hirata K., et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006, 51:363-368.
69. Wong K.K., Fracasso P.M., Bukowski R.M., Lynch T.J., Munster P.N., Shapiro G.I., et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009, 15:2552-2558.
70. Minkovsky N., Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Invest Drugs 2008, 9:1336-1346.
71. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
72. Solca F., Schweifer N., Baum A., Rudolph D., Amelsberg A., Himmelsbach F., et al. BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor, shows activity on L858R/T790 M EGFR mutants. Clinical Cancer Res 2005, 11:A242.
73. Perera S.A., Li D., Shimamura T., Raso M.G., Ji H., Chen L., et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 2009, 106:474-479.
74. Plummer R., Vidal L., Perrett R., Spicer J., Stopfer P., Shahidi M., et al. A Phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor. Eur J Cancer Suppl 2007, 5:108.
75. Spicer J., Calvert H., Vidal L., Azribi F., Perrett R., Shahidi M., et al. Activity of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR. J Thorac Oncol 2007, 2:S410.
76. Shih J.Y., Yang C.H., Su W.C., Hsia T.C., Tsai C.M., Chen Y.M., et al. A Phase II study of BIBW 2992, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activating EGFR mutations after failure of 1 line of chemotherapy (LUX-Lung 2). J Clin Oncol 2009, 27(Suppl. 15). Abstract 8013.
77. Yang C., Shih J., Su W., Hsia T., Ho C., Dudek A.Z., et al. BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaïve patients with adenocarcinoma of the lung and activating EGFR mutations. J Thorac Oncol 2009, 4(Suppl. 1). Abstract A3.3.
78. ClinicalTrials.gov. BIBW 2992 (TOVOK) and BSC versus placebo and BSC in non-small cell lung cancer patients failing erlotinib or gefitinib (LUX-LUNG 1), vol. 2008.
79. De Greve J., Teugels E., Geers C., DeMey J., In'tveld P., Decoster L., et al. Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations. Eur J Cancer Suppl 2009, 7:555-556.